TuHURA Biosciences (HURA) news
Recent news
Tuhura Biosciences receives new U.S. patent broadening coverage for its Vista inhibitor, TBS-2025
Tuhura Biosciences has been granted a new U.S. patent that expands the intellectual property coverage for its Vista inhibitor, TBS-2025. The patent, issued by the U.S. Patent and Trademark Office, provides additional legal protection for the compound, potentially extending the exclusivity period…
AInvest Wire · 1d agoTuhura Biosciences receives key U.S. patent for its groundbreaking delta opioid receptor (DOR) antibody drug conjugate (ADC) technology
AInvest Wire · Oct 5, 2026Tuhura Biosciences - May explore trial expansion & accelerated approval with FDA if response rates encouraging
TuHURA Biosciences is considering potential trial expansion and discussions with the FDA regarding accelerated approval pathways, contingent on encouraging response rates observed . The company recently received an update from the FDA, which lifted a partial clinical hold . This action allows for…
AInvest Wire · Sep 14, 2026Tuhura Biosciences gets FDA "study may proceed" notice & ind
TuHURA Biosciences, Inc. has received a notice from the U.S. Food and Drug Administration (FDA) allowing its clinical study to proceed following the removal of a partial clinical hold on its investigational therapy. This development marks a key regulatory milestone for the biotechnology firm, which…
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.